2020 American Society of Hematology Virtual Annual Meeting*

CAR T-cell therapy lisocabtagene maraleucel yields ORR of 84% (CR rate of 66%) among patients with relapsed/refractory MCL with a 3% incidence of grade ≥ 3 CRS.

Initial therapy with ibrutinib + venetoclax for 12 cycles resulted in a 1-year DFS rate of 95.3% in patients with uMRD who were subsequently randomized to placebo.

5-year analysis of the phase III MURANO trial continued to demonstrate the efficacy of venetoclax + rituximab in patients with relapsed/refractory CLL.

In ACE-CL-003, acalabrutinib plus venetoclax and an anti-CD20 antibody was generally well tolerated and yielded high CR/CRi and uMRD rates in both RR and TN CLL.

Post hoc exploratory analysis identified potential predictors of response to tazemetostat in patients with relapsed/refractory follicular lymphoma with WT and mutant EZH2, including rituximab refractoriness.

Umbralisib monotherapy associated with a 47% response rate in heavily pretreated patients with relapsed/refractory marginal zone lymphoma, follicular lymphoma, or small lymphocytic lymphoma.

In a pooled analysis, cardiac AEs occurred in 17% of patients with CLL treated with acalabrutinib monotherapy a large majority of whom had preexisting risk factors.

Parsaclisib active in BTK inhibitor–naive patients with R/R MZL across nodal, extranodal, or splenic subtypes.

Durable CRs observed among patients with highly refractory FL and DLBCL, including those previously receiving CAR T-cell therapy.

Among patients with cHL and a median age of 74 years, frontline brentuximab vedotin therapy was associated with ORR > 90%.

Updated results of the next-generation, noncovalent BTK inhibitor LOXO-305 suggest encouraging efficacy and safety in heavily pretreated patients with CLL/SLL.

In the phase III UNITY-CLL trial, umbralisib + ublituximab demonstrated superior PFS benefit vs chlorambucil + obinutuzumab in both previously untreated and previously treated patients with CLL.

Lisocabtagene maraleucel plus ibrutinib well tolerated with encouraging efficacy in heavily pretreated patients with CLL/SLL.

Axi-cel, a CD19-directed CAR T-cell therapy, produced high and durable response rates in patients with FL or MZL and ≥ 2 previous lines of therapy.

Early-phase trial of mosunetuzumab suggests both high rates and durable responses in a cohort of patients with heavily pretreated FL, including in POD24 and double refractory disease.